Edition:
India

Ardelyx Inc (ARDX.OQ)

ARDX.OQ on NASDAQ Stock Exchange Global Market

4.39USD
14 Oct 2019
Change (% chg)

$-0.26 (-5.59%)
Prev Close
$4.65
Open
$4.58
Day's High
$4.64
Day's Low
$4.38
Volume
111,045
Avg. Vol
191,813
52-wk High
$6.71
52-wk Low
$1.62

Latest Key Developments (Source: Significant Developments)

FDA - Ardelyx Gets FDA Approval For Ibsrela (Tenapanor) 50 Mg Tablets, For Oral Use
Friday, 13 Sep 2019 

Sept 12 (Reuters) - FDA::FDA - ARDELYX GETS FDA APPROVAL FOR IBSRELA (TENAPANOR) 50 MG TABLETS, FOR ORAL USE.FDA - APPROVAL FOR ARDELYX'S IBSRELA HAS BOXED WARNING FOR RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS.  Full Article

Ardelyx Receives FDA Approval For Ibsrela® (Tenapanor), An Nhe3 Sodium Transport Inhibitor, For The Treatment Of Irritable Bowel Syndrome With Constipation
Friday, 13 Sep 2019 

Ardelyx Inc ::ARDELYX RECEIVES FDA APPROVAL FOR IBSRELA® (TENAPANOR), AN NHE3 SODIUM TRANSPORT INHIBITOR, FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION.ARDELYX INC - CO IS "WELL POSITIONED" TO FILE NDA FOR HYPERPHOSPHATEMIA NEXT YEAR WITH POTENTIAL APPROVAL AND LAUNCH IN 2021.  Full Article

Ardelyx Reports Q2 Loss Per Share $0.41
Friday, 9 Aug 2019 

Aug 9 (Reuters) - Ardelyx Inc ::ARDELYX REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS.Q2 LOSS PER SHARE $0.41.Q2 EARNINGS PER SHARE ESTIMATE $-0.38 -- REFINITIV IBES DATA.AS OF JUNE 30, 2019, ARDELYX HAD TOTAL CAPITAL RESOURCES INCLUDING CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $123.9 MILLION.  Full Article

Ardelyx Reports Fourth Quarter 2018 Financial Results
Thursday, 7 Mar 2019 

March 6 (Reuters) - Ardelyx Inc ::ARDELYX REPORTS FOURTH QUARTER 2018 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.ARDELYX INC QTRLY LOSS PER SHARE $0.45.ARDELYX - AS OF DEC 31, 2018, HAD TOTAL CAPITAL RESOURCES INCLUDING CASH, CASH EQUIVALENTS & SHORT-TERM INVESTMENTS OF $168.1 MILLION.ARDELYX - MAINTAINS EXPECTATION THAT CASH, CASH EQUIVALENTS & SHORT-TERM INVESTMENTS WILL BE SUFFICIENT TO FUND CO'S OPERATIONS UNTIL AT LEAST EARLY 2021.  Full Article

Ardelyx Announces Pricing Of Public Offering Of Common Stock
Wednesday, 23 May 2018 

May 22 (Reuters) - Ardelyx Inc ::ARDELYX ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 12.5 MILLION COMMON SHARES PRICED AT $4.00PER SHARE.ARDELYX - EXPECTS TO USE NET PROCEEDS OF OFFERING TO SUPPORT ITS CLINICAL DEVELOPMENT, PRE-COMMERCIALIZATION EFFORTS FOR TENAPANOR, AMONG OTHERS.  Full Article

Ardelyx Raises $50 Mln In Loan Agreement With Solar Capital And Bridge Bank
Tuesday, 22 May 2018 

May 21 (Reuters) - Ardelyx Inc ::ARDELYX RAISES $50 MILLION IN LOAN AGREEMENT WITH SOLAR CAPITAL AND BRIDGE BANK.ARDELYX INC - $50 MILLION SENIOR SECURED TERM LOAN FACILITY HAS A MATURITY DATE OF NOVEMBER 1, 2022.  Full Article

Ardelyx Says Co Had About $134 Million In Cash
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Ardelyx Inc ::ARDELYX SAYS ON JAN 8, CO HAD ABOUT $134 MILLION IN CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS AS OF DEC 31, 2017 .  Full Article

Ardelyx Successfully Completes T3mpo-3 Safety Extension Study Of Tenapanor For Ibs-C
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Ardelyx Inc ::ARDELYX SUCCESSFULLY COMPLETES T3MPO-3 SAFETY EXTENSION STUDY OF TENAPANOR FOR IBS-C.ARDELYX - ‍RESULTS FROM BOTH T3MPO-1 AND T3MPO-2 STUDIES, SAFETY DATA, SUPPORT CO'S PLANS TO SUBMIT FIRST NDA TO U.S. FDA FOR THE INDICATION IN H2 2018​.ARDELYX INC - RESULTS FROM T3MPO-3 SHOWED THAT TENAPANOR WAS WELL-TOLERATED AMONG 240 PATIENTS TREATED.  Full Article

Ardelyx announces license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co for Tenapanor in China
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Ardelyx Inc ::Ardelyx announces license agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited for Tenapanor in China.Ardelyx - under terms of agreement, Ardelyx will receive upfront payment of $12 million, is eligible to receive additional milestones of up to $113 million.Ardelyx Inc - Fosun Pharma will have exclusive rights to market and sell Tenapanor in China.Ardelyx - under terms of agreement, co will receive tiered royalty payments on net sales from Tenapanor ranging from mid-teens to 20 percent.Ardelyx Inc - agreement also provides Fosun Pharma rights to commercialize Tenapanor for other indications for which it is approved in United States.  Full Article

Ardelyx Inc says has decided to discontinue development of RDX7675 for treatment of hyperkalemia​​
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Ardelyx Inc :Ardelyx announces updated development path for its cardiorenal pipeline.Ardelyx - second registration study for tenapanor for treatment of hyperphosphatemia will begin enrolling shortly​.Ardelyx - second registration study for tenapanor will begin enrolling shortly after having received feedback from U.S. FDA on trial design.Ardelyx Inc - ‍in addition, co reported clinically meaningful potassium lowering activity from its study for RDX7675 for treatment of hyperkalemia​.Says ‍however, company also observed an unexpected side effect of decreased serum bicarbonate​.Ardelyx Inc - ‍believes the side effect will limit commercial potential of RDX7675 and, as a result, has decided to discontinue development of RDX7675​.Ardelyx inc - ‍ Ardelyx will shift its hyperkalemia efforts to RDX013, its earlier-stage, small-molecule program​.Ardelyx Inc - the change will result in a cash savings of about $40 million to Ardelyx over next two years, extending co's operating runway into 2019​.  Full Article